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Abstract: The application of metallic nanoparticles (materials with size at least in one dimension
ranging from 1 to 100 nm) as a new therapeutic tool will improve the diagnosis and treatment of
diseases. The mitochondria could be a therapeutic target to treat pathologies whose origin lies in
mitochondrial dysfunctions or whose progression is dependent on mitochondrial function. We aimed
to study the subcellular distribution of 2–4 nm iron nanoparticles and its effect on mitochondrial DNA
(mtDNA), mitochondrial function, and autophagy in colorectal cell lines (HT-29). Results showed
that when cells were exposed to ultra-small iron nanoparticles, their subcellular fate was mainly
mitochondria, affecting its respiratory and glycolytic parameters, inducing the migration of the
cellular state towards quiescence, and promoting and triggering the autophagic process. These effects
support the potential use of nanoparticles as therapeutic agents using mitochondria as a target for
cancer and other treatments for mitochondria-dependent pathologies.
Keywords: nanotechnology; mitochondria; respiration; mtDNA deletions; copy number; metals
1. Introduction
Nanotechnology is referred to as the area of science focused on the study of the syn-
thesis, characterization, and application of materials and functional systems of particles
with sizes ranging between 1 and 100 nm. Nowadays, the interest in these materials is not
only due to their small size, but also at these dimensions the material properties change in
comparison to the same material at the macroscopic scale and make possible highly specific
cellular and molecular interactions. The application of nanotechnology to biomedical
research (nanobiotechnology) will improve, in the next few years, the development of new
and more effective tools for the detection and treatment of diseases like diabetes, Parkin-
son’s disease, or cancer [1,2]. This science will progress the monitorization, reparation,
and control of biological functions by using systems on a nanoscale. Despite the devel-
opment of nanoparticles for different biomedical applications, the exposition to certain
types of particles could promote cell damage. Nowadays, the accepted paradigms of the
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toxicity of nanomaterials are oxidative stress and inflammation. In fact, our research group
described the damage produced by Au (gold) nanoparticles in DNA structure, ROS pro-
duction, and lipid in vitro and in vivo conditions and its relation with the nanoparticle
size [3], but other mechanisms are still not well-defined.
Iron oxide nanoparticles are widely used in biomedical research, especially in cancer
research, due to their properties of magnetism, biocompatibility and due to their drug deliv-
ery and multi-imaging functions [4]. Even the treatment of anemia using iron nanoparticles
have been developed in the last years to reduce the side effects of traditional treatments
due to the reduced size of nanoparticles that could increase its absorption [5]. Moreover,
iron nanoparticles, especially the iron oxide, have been developed as an alternative in
gene therapy and as a drug delivery system [6]. Recent studies have been conducted
to evaluate some more specific and relevant aspects related to toxicity mechanisms of
iron oxide nanoparticles like mitochondrial damage, ROS production or autophagy [7].
Khan, M.I. and co-workers [8] showed that certain iron oxide nanoparticles promoted cell
death in lung cancer cells through ROS production and autophagy, but these nanoparticles
did not promote cell death in normal lung cells. On the other hand, other authors have
proposed the role of iron nanoparticles in autophagosome induction and oxidative damage
in mammary gland cells [9]. Nonetheless, more studies are necessary on the possible
interaction between iron nanoparticles and mitochondria. Autophagy is an intracellular
degradation process that delivers cytoplasmic constituents to lysosomes for degradation
in response to a high variety of stimuli [10]. This process is related to create new cellular
structures [11], so it represents a catabolic process of cytosolic renovation, but it is also able
to induce autophagy-dependent cell death [12]. There are defined three types of autophagy
depending on how the autophagic substrate move to the lysosome: macro-autophagy,
micro-autophagy, and chaperone-mediated autophagy. One of the effects of iron nanoparti-
cles could be associated with the induction of autophagy due to most endocytic routes of
nanomaterial cell uptake by phagocytic and non-phagocytic mechanisms converge upon
the lysosome.
In the present study, the effect of ultra-small iron nanoparticles on autophagy in-
duction and mitochondrial function are evaluated using an in vitro model. Two types of
ultra-small iron nanoparticles have been tested, a commercial preparation used in clinical
practice (Venofer®) and one synthesized in the laboratory (FeNPs). This work addresses,
for the first time, a comprehensive study about the traffic of iron and other elements
in the subcellular fractions, the integrity of the mtDNA, the mitochondrial functionality
and the induction of the autophagy process that will increase the knowledge about the
metabolism of nanoparticles and its possible application in therapy focused on mitochon-
dria. To perform the study HT-29 cell line was chosen based on previous studies in which
the implications of nanomaterials in therapy have been evaluated [13–15].
2. Materials and Methods
2.1. Synthesis and Characterization of Nanoparticles: Synthesis of Ultra-Small Nanoparticles
(FeNPs)
Iron nanoparticles (4 nm core Fe2O3 coated with tartaric/adipic acid) were synthesized
following a slightly modified protocol from Pereira et al. [16]. This method is based
on the precipitation of Fe3+ in the presence of highly basic medium (5 mol L−1 NaOH
solution) with the addition of tartrate and adipic acid solution for the iron core coating as
described somewhere else [15]. The molar ratio tartaric: adipic: Fe used corresponds to
1:1:2, which has given best performance in previous experiments. The three components
are mixed and constantly stirred in a buffer media (ammonium acetate 50 mmol L−1 at
pH 4). The initial pH of the mixture is increased stepwise until reaching pH 8. When
mixture turns dark brown/blackish, centrifugation and ultrafiltration (30,000 Da; 3000 Da
Ultra-15 MWCO centrifugal filter units, Millipore, Darmstadt, Germany) steps are needed
to separate the microparticulate and nanoparticulate iron fractions from the supernatant
and remove excess of soluble ligands and the rest of reagents. Centrifuge Biofuge Stratos
Heraeus (Thermo ScientificTM, Waltham, MA, USA) was used for these purposes. Size and
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shape characterization of the particles has been conducted by TEM, DLS, and UV-VIS.
The characterization of these nanoparticles was published in previous articles of our
research group [15].
2.2. Cell Culture Conditions
HT-29 cell lines were obtained from the Cell Culture Resource Centre at the University
of Granada, Spain. The cells were precultured in 25 cm2 culture flasks in RPMI-1640
medium supplemented with 10% (v/v) FBS and 2 mmol L−1 L-glutamine. The culture
flasks were maintained in a cell incubator at 37 ◦C in a humidified atmosphere of 5% CO2
and 95% air. Medium was replaced every 2–3 days after rinsing with PBS. Upon reaching
confluence, cells were treated with trypsin-EDTA solution (Sigma, St Louis, MO, USA) and
split 1/10 to allow for continuous growth. Cells were exposed to 0.5 mmol L−1 Fe NPs
concentration over 48 h. Cells cultured were treated with 0.5 mmol L−1 FeNPs or Venofer®
for 48 h. Every week, the absence of mycoplasma was evaluated employing a commercial
kit (Sigma, St. Louis, MO, USA).
2.3. TEM Analysis
Once the exposure time had finished, cells were prepared to be visualized by TEM.
Cells samples were fixed with fresh primary fixative (1.5% glutaraldehyde, 1.0% formalde-
hyde in 0.05 mol L−1 sodium cacodylate buffer, pH 7.4) and post-fixed with secondary
fixative (1% osmium tetroxide, 1% potassium ferrocyanide in Milli Q water) followed
by dehydration with ascending series of alcohol before embedding samples in epoxy
resin. Ultra-thin sections were cut and doubly stained with uranyl acetate and lead cit-
rate. A transmission electron microscope LIBRA 120 PLUS microscope at 120 kV (Carl
Zeiss SMT, Oberkochen, Germany) was used to determine the distribution of ultra-small
iron nanoparticles.
2.4. Subcellular Fractionation
HT-29 cells were previously washed with physiologic saline solution. Mitochondria
isolation was carried out employing a commercial kit according to the manufacturer’s
instruction (Abcam, Cambridge, UK). Briefly, cells were trypsinized, collected by centrifu-
gation and frozen. Then, cells were homogenized and centrifuged at 1000× g, 10 min, 4 ◦C,
two times. Both supernatants were collected and the pellet with the nucleus portion was
preserved. Afterward, the supernatants were centrifuged at 12,000× g during 10 min, 4 ◦C,
obtaining the pellet with the isolated of mitochondria. Supernatant was also preserved in
which ERP, Golgi, and cytosol was included.
2.5. Determination of Total Metal Concentrations
Determination of sodium (Na), magnesium (Mg), phosphorus (P), potassium (K),
calcium (Ca), iron (Fe), copper (Cu), manganese (Mn), zinc (Zn) and selenium (Se) in
subcellular fractions, diluted with a basic solution containing ammonium hydroxide,
butanol, EDTA, and triton X-100, was performed by means an ICP-MS instrument (Agilent
7500, Agilent Technologies, Tokyo, Japan) fitted with a Meinhard type nebulizer (Glass
Expansion, Romainmotier, Switzerland) and equipped with a He collision cell. A Milli-Q
system (Millipore, Bedford, MA, USA) was used to obtain deionized water (18 MΩ cm).
All reagents (ammonium hydroxide solution, butanol, EDTA, Triton X-100) used were of
the highest available purity. A standard solution of 100 µg L−1 of Li, Mg, Sc, Co, Y, In, Ce,
Ba, Pb, Bi, and U in 1% (v/v) HNO3 was prepared from a 1.000 mg L−1 multi-element stock
standard solution (Merck, Darmstadt, Germany) and used for daily optimizing of the ICP
parameters. Single-element standard solutions for ICP-MS containing 1.000 µg mL−1 of
each analyte were also purchased from Merck. Calibration curves were prepared using
Ga as an internal standard and by the dilution of stock solutions of 1.000 mg L−1 in 1%
HNO3. The accuracy of this method was evaluated by comparison with a certified reference
material SeronormTM Trace Elements Serum (Billingstad, Norway) and by recovery studies
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of spiked samples with multi-element standards. The calculated recoveries for each element
were between 95% and 105% in all cases. For each element, we used the mean of five
separate determinations.
2.6. Proportion of Deleted mtDNA and mtDNA Copy Number Assessment
The proportion of deleted mtDNA was determined using a quantitative reverse-
transcription polymerase chain reaction (QRT-PCR) to amplify two mitochondrial genes,
MT-ND4 and MT-ND1. Relative levels of mtDNA copy number were also determined by
QRT-PCR by amplifying the nuclear single-copy nuclear gene acidic ribosomal phosphopro-
tein PO (36B4) and using the amplification data of mitochondrial MT-ND1 gene previously
obtained. DNA amplification was performed in a MicroAmp Optical 384-well Reaction
Plate (Applied Biosystems, Foster City, CA, USA) using the Applied Biosystem’s 7900HT Fast
Real-Time PCR system. Primers for the assays were as follows: MT-ND1 forward primer 5′-
CCCTAAAACCCGCCACATCT′-3, MT-ND1 reverse primer GAGCGATGGTGAGAGCTAAGGT-
3′, MT-ND4 forward primer 5′-CCATTCTCCTCCTATCCCTCAAC-3′, MT-ND4 reverse
primer 5′-CACAATCTGATGTTTTGGTTAAACTATATTT-3′, 36B4 forward primer 5′-
CTGCAGATTGGCTACCCGAC-3′ and 36B4 reverse primer 5′-CACAGACAAAGCCAGGACCC-
3′. Final primer concentrations were 200 nmol L−1 except for the last two that were 300 and
500 nmol L−1, respectively. Reactions were performed in 10 µL volumes. Reaction mixture
in each well included genomic DNA (5 ng), 2× QuantiNova SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) (5 µL), ROX dye (Applied Biosystems,
Foster City, CA, USA) (1 µL), Mili-Q sterilized H2O and the proper primer oligonucleotides.
Reaction conditions were set at 95 ◦C for 2 min followed by 40 cycles of data collection
consisting of a denaturation step at 95 ◦C for 8 s and an annealing/extension at the 58 ◦C
step for 15 s. An additional phase to obtain a melting curve was performed at the end of
each reaction to verify specific amplification. Standard curves were included for analysis
of data. Mean quantification cycle (Cq) for each sample were calculated using Sequence
Detector Systems version 2.4 software. The proportion of deleted mtDNA was calculated
for each well dividing MT-ND4 by MT-ND1 amplification data taking into account reaction
efficiency values. The resulting values were divided by the average value obtained from
control samples (untreated cells) analysis. This allowed to obtain a relative MT-ND4:MT-
ND1 ratio. In turn, the MT-ND1:36B4 ratio was calculated and multiplied by two to obtain
mtDNA copy number for each sample. DNA used in the aforementioned assays was iso-
lated using a NucleoSpin Tissue kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany)
according to manufacturers.
2.7. Determination of Energetic Metabolism
2.7.1. Mitochondrial Respiration
The oxygen consumption rate (OCR) in HT-29 cells was measured in real-time using
a XF-24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA) as previ-
ously reported [17]. For this, 3 × 104 cells were seeded for 16 h in the XF-24 plate and
treated for 48 h on 0.5 mmol L−1 of FeNPs or VENOFER®. The medium was replaced with
450 µL/well of XF-24 running media (Seahorse Bioscience, Billerica, MA, USA), supple-
mented with 25 mmol L−1 glucose, 2 mmol L−1 glutamine, 1 mmol L−1 sodium pyruvate,
without serum and pre-incubated at 37 ◦C for 20 min in the XF Prep Station incubator
(Seahorse Bioscience, Billerica, MA, USA) in the absence of CO2. The plate was then trans-
ferred to the XF-24 Extracellular Flux Analyzer, and after an OCR baseline measurement,
four sequential injections of compounds that affect bioenergetics were performed, as fol-
lows: 55 µL of oligomycin (1 µg mL−1), 61 µL of 2,4-Dinitrophenol (2,4 DNP) (1 mmol L−1),
and 68 µL of antimycin A/rotenone (10 µmol L−1/1 µmol L−1) at injection in port C.
Each treatment was carried out in three replicates and the final results were expressed as
pmol of O2 consumed per 105 cells per minute (pmol O2/105 cells/min).
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2.7.2. Glycolysis
To evaluate glycolysis, extracellular acidification rate (ECAR) was measured in real-time
using a XF-24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA) as previ-
ously reported [17]. ECAR was measured after addition of 55 µL of rotenone (1 µmol L−1),
61 µL of glucose (30 mmol L−1) and 68 µL 2-Deoxy-d-glucose (2-DG) (100 mmol L−1).
Prior to measure ECAR, HT-29 cells were treated as in previous assay per triplicate and
average ECAR value, expressed as milli-pH per minute (mpH/min) per 3.0 × 104 cells,
was calculated for each treatment.
2.8. Autophagy
2.8.1. Autophagy Induction
The CYTO-ID ENZKIT175 Autophagy Detection Kit 2.0 (Enzo Life Sciences, Lausen,
Switzerland) was used for the detection of autophagy in HT-29 cells. Briefly, HT-29 cells
were seeded at a density of 0.75 × 105 cells/mL and left to adhere for 24 h. Then, cells were
treated with 0.5 mM FeNPs for 48 h, untreated (control group) or rapamycin 0.5 µmol L−1
(autophagy inductor) for 12 h. Then, the supernatant was removed and the cells were
washed twice with 200 µL of PBS supplemented with 5% (v/v) FBS and stained with an
autophagy staining solution containing CYTO-ID® Green Detection Reagent and Hoechst
33342 Nuclear Stain following the protocol provided by the manufacturer. Fluorescence
was determined using a microplate reader (Biotek, VT, USA), excitation 480 nm-emission
530 nm and also a confocal fluorescence microscope. For confocal fluorescence microscopy,
staining solution was removed after 30 min of incubation at 37 ◦C in a humidified incubator,
and cells were washed with 200 µL of PBS supplemented with 5% (v/v) FBS three times.
Then, cells were fixed with PFA 4% (v/v), at room temperature in the absence of light
for 20 min, and washed with 200 µL of PBS supplemented with 5% (v/v) FBS three
times. Then microscope slide preparation with glycerol and cells were visualized and
photographed in a confocal microscopy (Nikon, Tokyo, Japan) with a coupled camera (ref)
Nis-Elements microscope imaging software (version 4.13).
2.8.2. Autophagic Flux
The levels of p62 were assessed in cells by the p62 Elisa kit (Enzo Life Sciences, Lausen,
Switzerland) according to the manufacturer’s protocol. Briefly, after 48 h exposure to iron
nanoparticles and rapamycin 0.5 µmol L−1 (as positive control), cells were collected and
protein were extracted and seeded on a pre-coated plate with p62 antibody. After incubating
samples in presence of a second anti-p62 antibody (rabbit polyclonal), the amount of
p62 was revealed by adding a secondary donkey anti-rabbit IgG antibody conjugated to
horseradish peroxidase and a mix composed by TMB and hydrogen peroxide. The plate
was read in a microplate reader (Biotek, Winooski, VT, USA) and the amount of p62
normalized for the total protein amount.
2.9. Apoptosis/Necrosis
To quantify if nanoparticles induced apoptosis or necrosis in HT-29 cells, a double
staining with annexin V and propidium iodide was performed. Cells were seeded in
35 mm culture dishes (VWR, Radnor, PA, USA) at 2 × 105 cells/mL and incubated in
the conditions described in Section 2.2 Culture medium was removed after 24 h and
replaced with 1 mL of fresh medium containing either the IC50 of extracts or 0.4 µM of
doxorubicin (positive control). Cells were incubated for 48 h, collected by trypsinization
and centrifuged at 1000× g for 5 min at room temperature (RT). The obtained pellet
was rinsed twice with 1 mL of cold PBS 1× intercalated with 5 min of centrifugations at
1000× g. Following centrifugations, 100 µL of annexin binding buffer 1×, 5 µL of annexin
V-FITC and 2 µL of PI (Annexin V-FITC Apoptosis Detection Kit; Invitrogen, Waltham,
MA, USA) was added to all samples and incubated for 15 min at RT in the absence of light.
Afterwards, to these cellular suspensions were added 400 µL of annexin binding buffer 1×
and 500 µL of cold PBS 1×. The analysis and quantification of apoptotic events and necrosis
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were performed by flow cytometry on Attune Acoustic Focusing Flow Cytometer (Life
Technologies, Carlsbad, CA, USA) using an Attune Cytometric software (Life Technologies),
with the acquisition of at least 10,000 events per sample. Data presented as the mean of
two independent experiments.
2.10. Statistical Analysis
Descriptive statistical parameters (means and standard deviations of 8 samples for
each experiment) were obtained for each of the variables studied. Statistical comparisons
among the groups were performed by a comparison of means between independent vari-
ables. All analyses were performed using SPSS 20.0 (SPSS, Chicago, IL, USA). Differences
were considered statistically significant at a probability level <5%.
3. Results
3.1. TEM Images
Nanoparticles administered to the cells were observed by transmission electron mi-
croscopy (TEM). As shown in Figure 1, the presence of autolysosomes was found after 48 h
of exposure. This finding is compatible with the mitophagy process. No differences for the
presence of nanoparticles nor for the formation of autophagosomes were found between the
synthesized iron n anoparticles and the commercial form (Venofer®, Figure 1) administered.
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3.2. Total Metal Distribution
Table 1 shows the results of total metal concentration. The results showed that at basal
conditions, the highest levels of iron were found in the mitochondria fraction. When cells
were exposed to ultra-small FeNPs, the highest increase in the iron levels was also found for
the fraction corresponding to mitochondria. The methodology employed did not discern
if mitochondria are free of lysosomes, thus some lysosomal metals could be included in
this fraction.
On the other hand, in relation to the rest of the elements studied, at basal conditions,
the Mg levels found were significantly lower in the fraction corresponding to the nucleus,
the highest levels of Ca and Se were registered in the fraction corresponding to the nucleus
followed by the fraction corresponding to the mitochondria. Na and K levels were signifi-
cantly higher in cytosol than in other subcellular fractions. The levels of Cu in the fraction
corresponding to the nucleus were significantly higher than those found in the cytosol.
After exposing the cells to ultra-small FeNPs, there was an increase in all the other
elements studied in the fraction corresponding to the mitochondria, except for Cu. In the nu-
cleus, an increase in Cu levels was registered as a consequence of exposure to nanoparticles.
3.3. Proportion of Deleted mtDNA and mtDNA Copy Number
Figure 2 show the proportion of mtDNA deleted in HT-29 cells. No significant differ-
ences were found in this parameter between groups. However, when colorectal cells were
treated with both types of iron nanoparticles, mtDNA copy number was lower (Figure 3).
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Table 1. Metal concentrations in HT-29 subcellular fractions.
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Venofer® 1915.6 ± 6.6 a,b 432.2 ± 37.3 a 18,204.3 ± 463.9 a 1635.4 ± 584.6 1043.1 ± 12.5 2636.6 ± 27.8 a,b 3.7 ± 0.4 b 1.8 ± 0.02 b 71.0 ± 2.1 0.308 ± 0.02 a
Cytosol + Mb + Golgi
+ REP
Control 3561.4 ± 687.1 c 352.1 ± 43.9 c 4531.3 ± 445.2 4307.3 ± 805.6 c 386.8 ± 15.8 c 8.6 ± 0.04 c 0.4 ± 0.2 1.3 ± 0.2 43.3 ± 0.69 0.043 ± 0.01 c
Fe NPs 4193.0 ± 471.5 e 391.4 ± 9.5 5885.9 ± 525.2 e 4918.1 ± 305.3 e 496.7 ± 119.0 e 300.9 ± 37.8 a,e 0.3 ± 0.2 e 1.1 ± 0.2 45.4 ± 4.3 e 0.060 ± 0.03 e
Venofer® 4064.2 ± 193.1 g 451.8 ± 37.3 6579.2 ± 463.9 a,g 5359.3 ± 584.6 g 435.4 ± 12.5 a,g 388.2 ± 27.8 a,b,g 0.6 ± 0.1 g 1.6 ± 0.2 49.9 ± 2.1 a,g 0.104 ± 0.02 a,g
Nucleus
Control 898.6 ± 128.9 c,d 81.2 ± 32.7 d 5112.6 ± 3982.1 299.2 ± 137.7 c,d 717.1 ± 366.9 18.9 ± 7.3 2.0 ± 0.6 2.5 ± 0.1 d 77.6 ± 18.4 0.213 ± 0.01 c,d
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Venofer® 1046.2 ± 64.8 g,h 180.8 ± 26.4 a,b,g,h 11,586.2 ± 600.0 b,g,h 657.4 ± 126.9 b,g,h 978.6 ± 133.2 h 1271.1 ± 156.8 a,b,g,h 5.6 ± 0.7 a,g,h 4.4 ± 0.9 g,h 72.0 ± 25.3 0.175 ± 0.05
Statistics between groups within each subcellular fraction: a vs. control; b vs. Fe NPs; Statistics in each group among the different subcellular fractions; c vs. control group of the subcellular fraction corresponding
to Mitochondria + Peroxisome; d vs. control group of the subcellular fraction corresponding to Cytosol + Mb + Golgi + REP; e vs. Fe NPs group of the subcellular fraction corresponding to Mitochondria +
Peroxisome; f vs. Fe NPs group of the subcellular fraction corresponding to Cytosol + Mb + Golgi + REP; g vs. Venofer® group of the subcellular fraction corresponding to Mitochondria +Peroxisome; h vs.
Venofer® group of the subcellular fraction corresponding to Cytosol + Mb + Golgi + REP.
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3.4. Determination of Energetic Metabolism
The effects of nanoparticles on mitochondrial functionality were assessed firstly by
analyzing OCR by using Agilent Seahorse XF24 Analyzer (Figu e 4). Mea ured parameters
were basal respiration (which shows energetic demand of the cell under baseline condi-
tions), ATP production (that shows ATP produced by the mitochondria that contribute to
meeting the energetic needs of the cell), proton leak (that can be a sign of mitochondrial
damage or can be used as a mechanism to regulate the mitochondrial ATP production),
maximal respirati n (that shows the maximum rate of respiration that the cell can achieve)
and spare capacity (that represents the cell’s ability to respond to demand, and that can be
an indicator of cell fitness flexibility). Differences were found for maximal respiration and
spare capacity, with the highest value found for control group.
Concerning glycolysis, three parameters were measured (Figure 5), namely glycolysis
(presented as the ECAR reached by a given cell after the addition of saturating amounts of
glucose), glycolytic capacity (that represents the cell’s use of glycolysis to its maximum
capacity) and glycolytic reserve (that indicates the capability of a cell to respond to an
energetic demand as well as how close the glycolytic function is to the cell’s theoretical
maximum). For the three parameters, the iron nanoparticles led to lower values than control
and Venofer® groups. Treatment of cells with Venofer® led to lower values than control
group only for glycolysis and glycolytic capacity. Metabolic phenotype was calculated as
the ECAR:OCR ratio (Figure 6). The most relevant observation was that Fe NPs slightly
moved cells from a net glycolytic phenotype to a more quiescent state.




Figure 4. Modulation of mitochondrial respiration by iron nanoparticles in HT-29 cells. Cells were 
treated with DMEM (ctrl), iron nanoparticles Fe NPs or Venofer® for 24 h. OCR was determined 
by using the Seahorse XF-24 Extracellular Flux Analyzer after the sequential injections of oligomy-
cin (1 µg mL−1), 2,4-DNP (1 mmol L−1), and rotenone/antimycin (1 µmol L−1/10 µmol L−1). (A) shows 
OCR. (B) shows maximal respiratory capacity. (C) shows the spare capacity. Data are indicated as 
the mean ± SEM (n = 3). (a) vs. control; (b) vs. Fe NPs 0.5 mM (p < 0.05). 
Figure 4. Modulation of mitochondrial respiration by iron nanoparticles in HT-29 cells. Cells were
treated with DMEM (ctrl), iro nanoparticles Fe NPs or Venofer® for 24 h. OCR was determined by
using the Seahorse XF-24 Extracel ular l t r t e sequential injections of oligomycin
(1 µg mL−1), 2,4-DNP (1 mmol L−1), and rotenone/anti ycin (1 µ ol L−1/10 µmol L−1). (A) shows
OCR. (B) shows maximal respiratory capacity. (C) shows the spare capacity. Data are indicated as
the mean ± SEM (n = 3). (a) vs. control; (b) vs. Fe NPs 0.5 mM (p < 0.05).
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3.5. Autophagy
The assessment of autophagy in HT-29 cells was analyzed to verify whether iron
nanoparticles induced this process. For this purpose, fluorescence signal was performed
using two dyes: Hoechst 33342 dye, which is a cell permeable nucleic acid dye and Cyto-ID®
Green dye, a 488 nm excitable green fluorescent reagent, which becomes brightly fluorescent
in vesicles produced during autophagy (Enzo Life Sciences, Lausen, Switzerland) and
normalized with respect to the signal produces by non-treated cells. Treatment of HT-29
cells with FeNPs led to higher content of autophagic vacuoles with respect to those found
in control group, but lower than those found in cells treated with the inductor of autophagy
(Figure 7). Moreover, in confocal microscopy study, cells treated with FeNPs displayed
increased fluorescence in comparison to unexposed cells indicating higher content of
autophagic vacuoles. These results confirmed that the exposure of cells to FeNPs induced
autophagy process in HT-29 colorectal cells (Figure 8).




The assessment of autophagy in HT-29 cells was analyzed to verify whether iron na-
noparticles induced this process. For this purpose, fluorescence signal was performed us-
ing two dyes: Hoechst 33342 dye, which is a cell permeable nucleic acid dye and Cyto-ID® 
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Figure 7. Autophagy induction evaluated by fluorescence using a microplate reader in HT-29
normalized to control cells (untreated). 5 mmol L−1, rapamycin 0.5 µmol L−1 and control cells
(untreated). Results expressed as mean ± SEM. (a) vs. control; (b) vs. Fe NPs 0.5 mmol L−1 (p < 0.05).
On the other hand, Figure 9 shows that the incubation with FeNPs or rapamycin
reduced significantly the quantity of p62 protein with respect to control cells, providing
information about that the autophagic flux was initiated by the FeNPs exposition.
3.6. Apoptosis/Necrosis
Figure 10 shows that the exposition to FeNPs reduced significantly the % of live
cells respect untreated cells. Moreover, these nanoparticles increased the rate of apoptotic
and necrotic cells at the present conditions with respect to control cells. There were not
differences between ultra-small iron nanoparticles and IC50 of cis-platinum (cis-Pt).
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4. Discussion
The application of nanoparticles in biomedical therapies will make possible the de-
velopment of new diagnosis and treatment tools. One of the most promising aspect related 
to the use of nanoparticles in biomedicine therapy is its employ as carriers in gene therapy 
or drug delivery, due to its facility of synthesis, good biocompatibility and low toxicity
[18]. In the present study, the uptake and distribution of the iron nanoparticles in the dif-
ferent compartments of colorectal cells were qualitatively visualized by TEM and quanti-
fied by ICP-MS. Although there is an increasing number of studies focused on under-
standing the interaction between the particles and the biological systems, publications 
about the mechanism of uptake and biodistribution are not yet clear [19]. The results of
this study show that exposure of cells to ultra-small iron nanoparticles produced an in-
crease in the levels of all the elements studied in the subcellular fraction corresponding to 
the mitochondria except copper (which seems to be directed towards the nucleus where
an increase in its levels was detected). This traffic of elements towards this fraction could 
indicate their participation in the cellular processes involving mitochondria and lyso-
somes induced by iron nanoparticles that are detailed below. 
The results revealed that the greatest abundance of iron at baseline levels resides in 
the subcellular fraction corresponding to the mitochondria. It is possible that FeNP went 
to the mitochondria fraction through the endosome-lysosome-autolysosome pathway, in-
stead of going to mitochondria directly. After the exposure of the cells to the different
treatments with NPs, the results showed that iron levels increased in all subcellular frac-
tions, but especially in the fraction corresponding to the mitochondria, where levels in-
creased 62 fold when the cells were exposed to FeNP, and 94 fold when they were exposed 
to Venofer®. These results are consistent with those obtained by TEM and with previous 
experiments that revealed a faster solubilization of Venofer® than the synthetic FeNPs.
Such solubilization might increase the bioavailability of ionic Fe to get into the mitochon-
dria once the NPs have been internalized as such, as can be observed in Figure 1. It is
i re 10. l ti f t i necrosis by flo cyto etry. esults expressed as ean SEM.
(a) vs. control (p < 0.05).
4. isc ssio
The application of nanoparticles in biomedical therapies will make possible the devel-
opment of new diagnosis and treatment tools. One of the most promising aspect related to
the use of nanoparticles in biomedicine therapy is its employ as carriers in gene therapy or
drug delivery, due to its facility of synthesis, good biocompatibility and low toxicity [18].
In the present study, the uptake and distribution of the iron nanoparticles in the different
compartments of colorectal cells were qualitatively visualized by TEM and quantified by
ICP-MS. Although there is an increasing number of studies focused on understanding the
interaction between the particles and the biological systems, publications about the mecha-
nism of uptake and biodistribution are not yet clear [19]. The results of this study show
that exposure of cells to ultra-small iron nanoparticles produced an increase in the levels
of all the elements studied in the subcellular fraction corresponding to the mitochondria
except copper (which seems to be directed towards the nucleus where an increase in its
levels was detected). This traffic of elements towards this fraction could indicate their
participation in the cellular processes involving mitochondria and lysosomes induced by
iron nanoparticles that are detailed below.
The results revealed that the greatest abundance of iron at baseline levels resides in the
subcellular fraction corresponding to the mitochondria. It is possible that FeNP went to the
mitochondria fraction through the endosome-lysosome-autolysosome pathway, instead of
going to mitochondria directly. After the exposure of the cells to the different treatments
with NPs, the results showed that iron levels increased in all subcellular fractions, but es-
pecially in the fraction corresponding to the mitochondria, where levels increased 62 fold
when the cells were exposed to FeNP, and 94 fold when they were exposed to Venofer®.
These results are consistent with those obtained by TEM and with previous experiments
that revealed a faster solubilization of Venofer® than the synthetic FeNPs. Such solubiliza-
tion might increase the bioavailability of ionic Fe to get into the mitochondria once the
NPs have been internalized as such, as can be observed in Figure 1. It is known that iron is
transported to the mitochondria, where it is utilized for synthesis of cofactors essentials
for the function of enzymes involved in oxidation-reduction reactions, DNA synthesis and
repair, and a variety of other cellular processes. Nowadays, the trafficking of iron to the
mitochondria and normal mitochondrial iron metabolism, including heme synthesis and
iron-sulfur cluster biogenesis, are being investigated [20].
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There are different factors that could modify the clearance of this type of particles
into the cells, like size, shape, or surface properties [21]. Recently, Feng and co-workers [7]
studied the intracellular traffic of iron nanoparticles and the uptake in in vitro models.
In their study, the iron nanoparticles were deposited in the cell structure within membrane-
bound structures like lysosomes or endosome after the exposition, but not in mitochondria.
This fact could be due to the exposition time of these experiments (2 h). In this way,
the exposition time used in the present study (48 h) may explain a more compartmentalized
distribution of this type of particles. On the other hand, the reduced size of the particles
employed in the present study could promote the particles to cross the membranes and their
transport to the mitochondria. Nevertheless, other authors that studied the intracellular
traffic of other types of metallic nanoparticles, in particular, silver nanoparticles, suggested
that they could be located close to the mitochondria [22,23].
At the present time, iron nanoparticles are being developed as an effective carrier in
gene therapy [18]. In that way, some approaches based on metallic nanoparticles, like iron
oxide nanoparticles [24] or gold silver alloy nanoparticles [25] have been employed to
deliver genetic material to mitochondrial tissue. Therefore, ultra-small iron nanoparticles
could be employed as a new tool due to their small size to be directed to the mitochondria.
Therefore, after confirming the nanoparticles localization, we evaluated the integrity
of mitochondrial DNA and the respiratory activity of mitochondria. The effects of the
FeNPs on mitochondria was elucidated measuring mtDNA copy number and deletions,
and the respiratory activity. The ratio between the mtDNA genes ND4 and ND1 is con-
sidered as a marker of the so-called common deletion 20. This is because ND1 is in a very
stable region of the mtDNA. Meanwhile, ND4 is in the middle of the region that suffer
the common deletion [26]. mtDNA deletions may be considered as markers of mtDNA
damage of oxidative origin or other [27]. In the present study, cells exposed to FeNPs and
Venofer® did not cause changes in this ratio, which can be interpreted as the absence of
damage at the mtDNA. However, results showed a decrease in copy number of mtDNA.
mtDNA copy number is considered as an indirect marker of mitochondrial function [28].
Also, some authors related the low copy number with the decrease of mitochondrial replica-
tive activity [29] or with an increase in mitochondrial destruction for example through
autophagy 11.
Results found in an mtDNA copy study were confirmed after analyzing mitochondrial
respiration by Seahorse technology. In fact, Figure 5 shows how the ultra-small FeNPs
affect maximal respiration and mitochondrial spare respiratory capacity, which is regarded
as an important aspect of mitochondrial function and is defined as the difference between
basal ATP production and its maximal activity. When cells are subjected to stress, energy
demand increases, requiring more ATP to maintain cellular functions. A cell with a larger
spare respiratory capacity can produce more ATP and overcome more stress, including
oxidative stress [30]. Overall, changes found in mitochondrial function after nanoparticles
administration present a very interesting opportunity for ultra-small iron nanoparticles
as antiproliferative agents in cancer, since they would allow the reduction of metabolic
activity in cancer cells when administered locally in the tumor, without causing alterations
in mitochondrial DNA from adjacent healthy cells.
Then, from the study, it can be demonstrated that iron particles decreased mitochon-
dria functionality without increasing mtDNA damage. This could be used to promote
cell death using the mitochondria as a target, when necessary, without affecting healthy
neighbor cells. Preserving the integrity of the mtDNA of adjacent cells is a very impor-
tant advantage of this possible therapeutic tool when it is administered locally, since the
strategy of producing cell death through oxidative damage is not very selective and could
compromise neighboring cells. Some of these effects of nanomaterials have been proposed
previously by other authors [9], but the effect on the respiratory function have not been
elucidated yet. Consequently, the present work could contribute to understanding the
relation between iron nanoparticles and mitochondrial function.
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Autophagy is an intracellular degradation process associated with an appropriate
replacement of certain types of cellular organelles, and it is important for the cell [12].
Some authors have proposed autophagy as one of the possible mechanisms of the nanopar-
ticle mechanism of action in cells [31]. In that way, the exposition of different cell lines to
metallic nanoparticles has been related to the activation of the autophagic process [4]. Cer-
tain authors [32] showed that rare-earth elements nanoparticles, samarium (Sm)/europium
(Eu) and gadolinium (Gd)/terbium(Tb), induced severe autophagy in cervical cancer cells
(HeLa). Sun and co-workers [33] demonstrated the autophagic process and the mitochon-
drial damage of silica particles in hepatocytes. The relation of autophagy in mitochondria
has not been deeply studied. Yoo and co-workers [34] suggested that one link between
autophagy and mitochondria is the process called mitophagy, the selective degradation of
mitochondria by autophagy. By means of this process, the excess or defective mitochondria
following damage or stress (i.e., oxidative stress) is removed. Damaged mitochondria
cause a depletion in ATP and a release of cytochrome c, which leads to activation of cas-
pases and onset of apoptosis. This process courses with the sequestration and hydrolytic
degradation by lysosomes [35,36]. In our study, confocal microscopy results suggested a
greater autophagic activity in FeNP-treated cells. This result agrees with those obtained
from the TEM images.
Moreover, to determine if the autophagic flux was initiated by the FeNPs, p62 was
determined. In that way, p62 decreased when cells were treated with nanoparticles produc-
ing a similar effect of rapamycin. In that way, p62 low levels and high levels of autophagy
induction could suggest that the beginning of the autophagic process was mediated by the
nanomaterials [37]. Consequently, these nanoparticles induced the autophagy in cells.
Furthermore, the ability of ultra-small iron nanoparticles to induce apoptosis/necrosis
in colorectal tumoral cells was evaluated. Figure 10 shows that at the present conditions
FeNPs induced mainly apoptosis and low necrosis levels at similar conditions that IC50
cis-platinum promoted. The role of iron nanoparticles in the cell death mechanism has
been previously investigated by other authors that described that the rate of apoptosis
induction depends on the size, form, and shape of nanomaterials [7]. Indeed, this effect
could be mediated by the capacity of Fe to conjugate with ROS and affect cell membranes,
proteins, or mitochondria [38].
Indeed, the results obtained showed that ultra-small nanoparticles could be used to
promote cell death using the mitochondria as a target, when necessary, although the impact
on healthy neighbor cells remains to be determined.
In a previous investigation from our research group [15], it was observed that the
same FeNPs tested in this study increased ROS generation, which could lead to an in-
creased mitochondrial autophagy as consequence of the increased oxidative damage at this
organelle. This situation would cause the reported fall in mitochondrial respiration, as well
as in glycolytic capacity. This sequence of events would be responsible for the entry of the
cells into the quiescence state.
5. Conclusions
In conclusion, under the experimental conditions of this study, when the colorectal
cells were exposed to the ultra-small iron nanoparticles tested, they reached the subcellu-
lar compartment corresponding to the mitochondria, quantitatively finding the highest
levels of iron in the aforementioned compartment. Electron microscopy studies showed
the presence of autolysosomes after 48 h of exposure, compatible with the mitophagy
process. Exposure to ultra-small iron nanoparticles did not cause deletions in mtDNA,
but a reduction in the number of mtDNA copies, indicative of a reduction in the number
of mitochondria in these tumor cells. Mitochondrial functionality studies demonstrated a
reduction in respiration parameters and a decrease in cellular glycolytic metabolic activity,
which are the logical consequence of the reduction in the number of mitochondrial copies.
Treatment with synthesized ultra-small iron nanoparticles resulted in the migration of the
cellular state towards quiescence. Finally, autophagy studies using confocal fluorescent mi-
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croscopy corroborated the images obtained by electron microscopy, reinforcing the presence
of the mitophagy process. All these results make ultra-small iron nanoparticles a relevant
tool for use as a therapeutic agent in mitochondria-dependent diseases, such as cancer.
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